D
David A. Mankoff
Researcher at University of Pennsylvania
Publications - 391
Citations - 18097
David A. Mankoff is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 73, co-authored 367 publications receiving 16229 citations. Previous affiliations of David A. Mankoff include University of Washington Medical Center & Seattle Cancer Care Alliance.
Papers
More filters
Journal ArticleDOI
Vorinostat to restore sensitivity to aromatase inhibitor therapy in metastatic breast cancer: A phase II clinical trial with ER imaging correlates.
Hannah M. Linden,Brenda F. Kurland,Jeanne M. Link,Vijayakrishna K. Gadi,Jennifer M. Specht,Julie Gralow,Erin K. Schubert,Lanell M. Peterson,Janet F. Eary,David A. Mankoff +9 more
TL;DR: It is hypothesized that HDACi therapy could restore sensitivity to aromatase inhibitor (AI) therapy, in patients with prior progression on AI, and allow continued endocrine therapy.
Journal Article
Cardiac Applications of Positron Emission Tomography
TL;DR: This is the second in a series of four continuing education articles on positron emission tomography (PET) imaging that the reader should be able to understand the clinical considerations for PET imaging of the heart and understand the technical considerations.
Journal ArticleDOI
Serial FDG-PET to predict response, time to skeletal related events, and survival in patients with bone-dominant metastatic breast cancer.
Jennifer M. Specht,Lanell M. Peterson,Alena Novakova,Janet O'Sullivan,Finbarr O'Sullivan,Andrew Shields,Susan Montgomery,Hannah M. Linden,Julie R. Gralow,Georgiana K. Ellis,Vijayakrishna K. Gadi,William E. Barlow,Robert K. Doot,Erin K. Schubert,Lisa K. Dunnwald,Lawrence R. MacDonald,Paul E. Kinahan,David A. Mankoff +17 more
TL;DR: FDG-PET was used to assess TTP, SRE and survival (OS) in patients starting a new bone lesions treatment in patients with central giant cell granuloma in this prospective study.
Journal ArticleDOI
ACRIN 6684 assessment of tumor hypoxia in glioblastoma using 18F-fluoromisonidazole with PET and MRI.
Elizabeth R. Gerstner,Zheng Zhang,James R. Fink,Gregory A. Sorensen,Darryl L'Heureux,Martha L. Heckel,Bernadine Dunning,Mark Muzi,David A. Mankoff,Daniel P. Barboriak +9 more
TL;DR: 18F-Fluoromisonidazole (FMISO) is a PET radiotracer whose uptake in hypoxic tissues can be measured radiographically and knowledge of the degree/distribution of tumor hypoxia by PET uptake and perfusion MRI parameters may provide prognosis.